Autoimmune and Immune-Mediated Disease
Zenas Biopharma (USA) LLC funds clinical research in IgG4-related disease, systemic lupus erythematosus, and warm autoimmune hemolytic anemia, with a clear focus on conditions driven by immune dysregulation and inflammatory activity.
- IgG4-related disease
- Systemic lupus erythematosus
- Warm autoimmune hemolytic anemia
Its research interests include disease control, flare prevention, anemia-related outcomes, and the management of immune-mediated tissue involvement.
Multiple Sclerosis
The sponsor supports studies in both relapsing multiple sclerosis and primary progressive multiple sclerosis, reflecting involvement across distinct forms of chronic neurologic disease.
- Relapsing multiple sclerosis
- Primary progressive multiple sclerosis
Areas of interest include lesion suppression, disability progression, and broader neurologic disease activity in multiple sclerosis.
B-cell and Immune Pathway Modulation
Across its portfolio, the company’s clinical activity is centered on therapies targeting immune signaling pathways relevant to B-cell-mediated disorders and other autoimmune diseases.
- B-cell-related immune modulation
- Autoimmune disease activity control
- Inflammatory disease management
This includes therapeutic interest in reducing pathologic immune activation and improving organ-specific and systemic disease manifestations.
Hematologic Autoimmunity
Clinical research in warm autoimmune hemolytic anemia highlights the sponsor’s interest in immune-driven blood disorders, especially those affecting red blood cell survival and anemia burden.
- Autoimmune hemolysis
- Anemia outcomes
- Rescue therapy reduction
The therapeutic emphasis includes restoration of hemoglobin response and control of clinically significant hemolytic activity.
